Poolbeg Pharma (LON:POLB) Stock Price Breaks Below Two Hundred Day Moving Average – Here’s What Happened

Poolbeg Pharma PLC (LON:POLB) shares passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of GBX 6.11 and traded as low as GBX 6. Poolbeg Pharma shares last traded at GBX 6, with a volume of 879,493 shares changing hands.

Analysts Set New Price Targets

Separately, Shore Capital Group restated a “house stock” rating on shares of Poolbeg Pharma in a research report on Thursday, September 24th.

Poolbeg Pharma Stock Performance

The firm’s fifty day moving average is GBX 7.46 and its 200 day moving average is GBX 6.11. The company has a market cap of £45.81 million, a PE ratio of -7.59 and a beta of 1.84.

Poolbeg Pharma (LON:POLB) last posted its quarterly earnings data on Tuesday, September 29th. The company reported GBX (0.28) earnings per share (EPS) for the quarter. As a group, sell-side analysts anticipate that Poolbeg Pharma PLC will post -0.68 EPS for the current fiscal year.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.